EA202092489A1 - СЕЛЕКТИВНЫЙ СТИМУЛЯТОР Treg RUR20kD-IL-2 И РОДСТВЕННЫЕ КОМПОЗИЦИИ - Google Patents

СЕЛЕКТИВНЫЙ СТИМУЛЯТОР Treg RUR20kD-IL-2 И РОДСТВЕННЫЕ КОМПОЗИЦИИ

Info

Publication number
EA202092489A1
EA202092489A1 EA202092489A EA202092489A EA202092489A1 EA 202092489 A1 EA202092489 A1 EA 202092489A1 EA 202092489 A EA202092489 A EA 202092489A EA 202092489 A EA202092489 A EA 202092489A EA 202092489 A1 EA202092489 A1 EA 202092489A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rur20kd
treg
related compositions
selective
compositions
Prior art date
Application number
EA202092489A
Other languages
English (en)
Inventor
Питер Бенедикт Кирк
Джон Л Ланговски
Джонатан Залевский
Original Assignee
Нектар Терапьютикс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нектар Терапьютикс filed Critical Нектар Терапьютикс
Publication of EA202092489A1 publication Critical patent/EA202092489A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Данное изобретение предусматривает композиции селективных стимуляторов Treg, включая RUR20kD-IL-2 и родственные композиции, и способы применения таких композиций, например, для лечения аутоиммунных заболеваний и/или других состояний, поддающихся лечению, которые эффективно обеспечивают селективного увеличение количества и активации регуляторных T-клеток по сравнению с эффекторными T-клетками.
EA202092489A 2018-05-21 2019-05-20 СЕЛЕКТИВНЫЙ СТИМУЛЯТОР Treg RUR20kD-IL-2 И РОДСТВЕННЫЕ КОМПОЗИЦИИ EA202092489A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862674244P 2018-05-21 2018-05-21
PCT/US2019/033100 WO2019226538A1 (en) 2018-05-21 2019-05-20 SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS

Publications (1)

Publication Number Publication Date
EA202092489A1 true EA202092489A1 (ru) 2021-03-16

Family

ID=67002369

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092489A EA202092489A1 (ru) 2018-05-21 2019-05-20 СЕЛЕКТИВНЫЙ СТИМУЛЯТОР Treg RUR20kD-IL-2 И РОДСТВЕННЫЕ КОМПОЗИЦИИ

Country Status (20)

Country Link
US (1) US20210205413A1 (ru)
EP (1) EP3796940A1 (ru)
JP (2) JP7235772B2 (ru)
KR (1) KR20210002577A (ru)
CN (1) CN112399859A (ru)
AU (2) AU2019274409B2 (ru)
BR (1) BR112020021564A2 (ru)
CA (1) CA3100204A1 (ru)
CL (1) CL2020003008A1 (ru)
CO (1) CO2020014510A2 (ru)
CR (1) CR20200546A (ru)
DO (1) DOP2020000212A (ru)
EA (1) EA202092489A1 (ru)
EC (1) ECSP20074392A (ru)
IL (1) IL278528B1 (ru)
JO (1) JOP20200290A1 (ru)
PE (1) PE20211307A1 (ru)
PH (1) PH12020551976A1 (ru)
SG (1) SG11202011242SA (ru)
WO (1) WO2019226538A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021206449A1 (en) 2020-01-10 2022-07-21 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
CN113121670B (zh) * 2020-01-15 2022-11-22 天津键凯科技有限公司 二取代peg化白细胞介素2及其制备方法、应用
EP4092048A4 (en) * 2020-01-15 2023-07-26 Jenkem Technology Co. Ltd. (Tianjin) METHOD FOR PREPARING PEGYLATED BIOMOLECULES HAVING CONTROLLABLE BINDING SITES
US20230272001A1 (en) * 2020-05-22 2023-08-31 Merck Sharp & Dohme Llc Novel processes for preparing conjugates of the il-2 protein
TW202228784A (zh) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
WO2022109477A1 (en) * 2020-11-23 2022-05-27 University Of Florida Research Foundation, Incorporated Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes
CA3239501A1 (en) 2021-12-14 2023-06-22 Ali ASHRAFZADEH Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401756A (en) 1981-04-14 1983-08-30 Immunex Corporation Process for preparing human interleukin 2
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5153310A (en) 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
FR2826365B1 (fr) 2001-06-20 2003-09-26 Oreal Compositions cosmetiques photoprotectrices contenant des derives amides, sulfonamides ou carbamates aromatiques d'acrylonitrile et nouveaux derives amides, sulfonamides ou carbamates d'acrylonitrile
ES2725808T3 (es) 2003-05-23 2019-09-27 Nektar Therapeutics Derivados de PEG que contienen dos cadenas de PEG
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
US7567215B1 (en) 2007-10-23 2009-07-28 The United States Of America As Represented By The Secretary Of The Navy Portable and inflatable antenna device
KR102591732B1 (ko) * 2010-11-12 2023-10-19 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
WO2012123381A1 (en) * 2011-03-11 2012-09-20 Assistance Publique - Hôpitaux De Paris Use of low dose il-2 for treating autoimmune - related or inflammatory disorders
JP6911044B2 (ja) * 2016-03-16 2021-07-28 シェ、ヤンホイＸｉｅ Ｙａｎｈｕｉ 呼吸器系疾患の治療のためのグルココルチコイドとポリエチレングリコール修飾インターロイキン２の組合せ

Also Published As

Publication number Publication date
US20210205413A1 (en) 2021-07-08
AU2019274409B2 (en) 2022-07-14
CA3100204A1 (en) 2019-11-28
ECSP20074392A (es) 2021-03-31
JOP20200290A1 (ar) 2020-11-15
EP3796940A1 (en) 2021-03-31
JP7235772B2 (ja) 2023-03-08
PE20211307A1 (es) 2021-07-20
AU2019274409A1 (en) 2020-11-12
JP2021523922A (ja) 2021-09-09
WO2019226538A1 (en) 2019-11-28
IL278528B1 (en) 2024-06-01
CR20200546A (es) 2021-05-18
PH12020551976A1 (en) 2021-09-13
BR112020021564A2 (pt) 2021-03-02
CO2020014510A2 (es) 2021-03-08
DOP2020000212A (es) 2021-03-15
IL278528A (ru) 2021-01-31
JP2023052053A (ja) 2023-04-11
AU2022246440A1 (en) 2022-11-03
CN112399859A (zh) 2021-02-23
CL2020003008A1 (es) 2021-07-30
SG11202011242SA (en) 2020-12-30
KR20210002577A (ko) 2021-01-08

Similar Documents

Publication Publication Date Title
EA202092489A1 (ru) СЕЛЕКТИВНЫЙ СТИМУЛЯТОР Treg RUR20kD-IL-2 И РОДСТВЕННЫЕ КОМПОЗИЦИИ
EA202091809A1 (ru) Агонистические антитела против pd-1 и их применение
EA202091484A1 (ru) 4-азаиндольные соединения
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA202190073A1 (ru) Композиции и способы лечения видов гемоглобинопатии и талассемии
EA201890161A1 (ru) Терапевтические композиции, комбинации и способы применения
EA202091479A1 (ru) Арил- и гетероарилзамещенные индольные соединения
TR201901445T4 (tr) Il2rbeta/yaygın gamma zinciri antikorları.
EA202091480A1 (ru) Аминоиндольные соединения, пригодные в качестве ингибиторов tlr
EA201890051A1 (ru) Композиции, содержащие бактериальные штаммы
EA201391755A1 (ru) Анти-kir антитела для лечения воспалительных заболеваний
EA202190368A1 (ru) Модифицированные пакеты-мессенджеры растений и варианты их применения
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
EA201891440A1 (ru) Составы/композиции, содержащие ингибитор btk
EA201792561A1 (ru) Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
EA201892203A1 (ru) Оксабороловые сложные эфиры, их применение
CY1121933T1 (el) Υποκατεστημενες δικυκλικες διυδροπυριμιδινονες και χρηση αυτων ως αναστολεις δραστικοτητας ελαστασης ουδετεροφιλου